Mazza Danielle
MD, MBBS, FRACGP, DRANZCOG, GradDipWomsHlth, is Head, Department of General Practice, School of Primary Health Care, Monash University, Victoria.
Aust Fam Physician. 2017;46(5):301-304.
In Australia, use and understanding of emergency contraception among women remains relatively low. This is despite the introduction of levonorgestrel emergency contraceptive pills (ECPs) more than a decade ago. In April 2016, a new ECP with the active ingredient ulipristal acetate became available in Australia.
The aims of this article are to increase understanding of the recently introduced ulipristal acetate ECP, including its safety profile, effi-cacy and special considerations; dispel common myths and misconceptions about emergency contraception; and to provide guidance on emergency contraceptive management in general practice, considering the recent advances.
Women are more receptive to information about emergency contraception that has been provided by a general practitioner (GP). As such, the availability of the ulipristal acetate ECP in Australia provides an important opportunity for GPs to help women prevent unplanned pregnancies.
在澳大利亚，女性对紧急避孕的使用和了解程度仍然相对较低。尽管十多年前就已引入左炔诺孕酮紧急避孕药（ECP），情况依然如此。2016年4月，一种含有活性成分醋酸乌利司他的新型紧急避孕药在澳大利亚上市。
本文旨在增进对最近引入的醋酸乌利司他紧急避孕药的了解，包括其安全性、有效性及特殊注意事项；消除关于紧急避孕的常见误解和错误观念；并结合最新进展，为全科医疗中的紧急避孕管理提供指导。
女性更容易接受全科医生（GP）提供的关于紧急避孕的信息。因此，醋酸乌利司他紧急避孕药在澳大利亚上市，为全科医生帮助女性预防意外怀孕提供了一个重要契机。
